Discovery of Novel Indazole Chemotypes as Isoform-Selective JNK3 Inhibitors for the Treatment of Parkinson’s Disease

• Published in: Journal of medicinal chemistry 2023-01, Vol.66 (2), p.1273-1300
• Main Authors: Shuai, Wen, Bu, Faqian, Zhu, Yumeng, Wu, Yongya, Xiao, Huan, Pan, Xiaoli, Zhang, Jifa, Sun, Qiu, Wang, Guan, Ouyang, Liang
• Format: Article
• Language: English
• Subjects: Humans; Indazoles - pharmacology; Indazoles - therapeutic use; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinase 10; Parkinson Disease - drug therapy; Phosphorylation; Protein Isoforms
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/acs.jmedchem.2c01410

c-Jun N-terminal kinases (JNKs) are involved in the pathogenesis of various diseases. In particular, JNK3 and not JNK1/2 is primarily expressed in the brain and plays a key role in mediating neurodegenerative diseases like Parkinson’s disease (PD). Due to the sequence similarity of JNK isoforms, developing isoform-selective JNK3 inhibitors to evaluate their biological functions and therapeutic potential in PD has become a challenge. Herein, docking-based virtual screening and structure–activity relationship studies identified 25c with excellent inhibitory activity against JNK3 (IC50 = 85.21 nM) and exhibited an over 100-fold isoform selectivity for JNK3 over JNK1/2 and remarkable kinase selectivity. 25c showed neuroprotective effects on in vitro and in vivo PD models by selectively inhibiting JNK3. Meanwhile, 25c showed an ideal blood–brain barrier permeability and low toxicity. Overall, this study provided a valuable molecular tool for investigating the role of JNK3 in PD and a solid foundation for developing JNK3-targeted drugs in PD treatment.